Genscript Biotech Corporation (G51) — Capital Reinvestment Ratio
Genscript Biotech Corporation (G51) has a Capital Reinvestment Ratio of 0.26x as of December 2025, meaning it reinvests 0% of its operating cash flow (€325.52 Million) in capital expenditures (€83.84 Million). See Genscript Biotech Corporation free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Genscript Biotech Corporation Capital Reinvestment Ratio (2016–2025)
This chart tracks Genscript Biotech Corporation's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Genscript Biotech Corporation (2016–2025)
Year-by-year Capital Reinvestment Ratio for Genscript Biotech Corporation from 2016 to 2025. For live market cap and broader valuation context, see market value of Genscript Biotech Corporation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | €325.52 Million | €83.84 Million | ▼ -86.8% |
| 2024 | 1.96x | €75.65 Million | €147.92 Million | ▲ +749.2% |
| 2018 | 0.23x | €307.66 Million | €70.84 Million | ▼ -83.2% |
| 2017 | 1.37x | €21.37 Million | €29.21 Million | ▲ +406.6% |
| 2016 | 0.27x | €33.27 Million | €8.98 Million | — |